Clinical Trial Update: Selinexor and Pembrolizumab for the Treatment of Cisplatin-Ineligible or Cisplatin-Refractory Locally Advanced or Metastatic Urothelial Carcinoma [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 trial evaluating the combination of selinexor and pembrolizumab in cisplatin-ineligible or cisplatin-refractory locally advanced or metastatic uroth…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• XPOVIO (selinexor)

Snippet

Sponsor: Mamta Parikh | Conditions: Advanced Urothelial Carcinoma, Locally Advanced Urothelial Carcinoma | Phase 1, Phase 2 | Status: TERMINATED | Results posted: 2026-01-29